Merger Mania: Impact on the Medical Information Department
- PDF / 386,053 Bytes
- 6 Pages / 504 x 719.759 pts Page_size
- 63 Downloads / 198 Views
0092-8615/2000 Copyright 0 ZOO0 Drug Information Association Inc.
Printed in the USA. All rights reserved.
MERGER MANIA: IMPACT ON THE MEDICAL INFORMATION DEPARTMENT COLLEEN M. CULLEY, PHARMD Medical Information Resident, Aventis Pharmaceuticals Inc, Kansas City, Missouri
KIRKH. HOFFMAN,PHD, RPH Director, Medical Informatics, Cell Pathways Inc, Horsham. Pennsylvania
ROMANASLAVIK, PHARMD Manager, Medical Informatics, Aventis Pharmaceuticals, Kansas City, Missouri
The purpose of this project was to create an eflcient, stepwise approach to integrating two medical information departments of merging pharmaceutical companies. This project may serve as a template for medical information departments in future mergers. The approach to this project will be a combination of past experiences, forward thinking, and observation during the merger currently in progress between Hoechst Marion Roussel and Rh6ne-Poulenc Rorer to become Aventis Pharmaceuticals, Inc. The current state of each medical information department was assessed, including workload statistics, function and responsibility, organizational structure, handling of calls, resources, and budget. Best practices for the integrated medical information department were established. A timeline and product information data sheet were createdfor merging the medical informarion departments to meet the best practice needs. This project serves as the first published literature on the impact of a merger on the medical information department, Key Words: Medical information; Merger; Pharmaceutical industry
BACKGROUND MERGERS IN THE PHARMACEUTICAL industry have become commonplace in the last 20 years. During the years of 1985 to 1991, a total of 12 major mergers occurred in the United States pharmaceutical industry (1,2). This trend has continued through the 1990s with such mergers as Pharmacia and Upjohn (Pharmacia & Upjohn), Glaxo and
Presented in poster form at the DIA “Medical Communications Meeting,” March 13, 2000, Washington, District of Columbia. Reprint address: Colleen M. Culley, PharmD, University of Pittsburgh Drug Information Center, 137 Victoria Hall, 200 Lothrop St., Pittsburgh. PA 15213.
Burroughs Wellcome (Glaxo Wellcome), and Ciba-Geigy and Sandoz (Novartis) (3). During 1999 to 2000 mergers between Hoechst Marion Roussel and Rhone-Poulenc Rorer (Aventis Pharmaceuticals), Glaxo Wellcome and SmithKline Beecham (new name unknown), Pharmacia & Upjohn and Monsanto (new name unknown), Pfizer Inc. and Warner-Lambert Company (Pzifer Inc.), and Astra and Zeneca (AstraZeneca) were announced. The importance and expense of innovative research and development drive these mergers in an extremely competitive global industry. Integrating two companies is a difficult process that begins with identifying new organizational structures and visions and ends with the merging of individual departments.
1163
Colleen M. Culley, Kirk H. Hoffman, and Romana SIavik
1164
PURPOSE Medical information departments of pharmaceutical companies are essential for providing drug information
Data Loading...
